Pages that link to "Q44333619"
Jump to navigation
Jump to search
The following pages link to Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). (Q44333619):
Displaying 50 items.
- The oral glucose tolerance test (OGTT) revisited (Q22252223) (← links)
- Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome (Q24816197) (← links)
- Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature (Q26749095) (← links)
- Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus (Q26777076) (← links)
- Whey protein: The "whey" forward for treatment of type 2 diabetes? (Q26777875) (← links)
- Glycemic Variability: How Do We Measure It and Why Is It Important? (Q26795377) (← links)
- Application of glycated hemoglobin in the perinatal period (Q26849479) (← links)
- Impact of postprandial glycaemia on health and prevention of disease (Q26862823) (← links)
- Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making (Q26992979) (← links)
- Lixisenatide as add-on therapy to basal insulin (Q27007547) (← links)
- Common standards of basal insulin titration in type 2 diabetes (Q27009355) (← links)
- Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists (Q28077026) (← links)
- Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience (Q28085428) (← links)
- 24-hour glycemic variations in drug-naïve patients with type 2 diabetes: a continuous glucose monitoring (CGM)-based study (Q28534980) (← links)
- Effect of Peripheral Electrical Stimulation (PES) on Nocturnal Blood Glucose in Type 2 Diabetes: A Randomized Crossover Pilot Study (Q28555152) (← links)
- Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes (Q28732681) (← links)
- Summation of blood glucose and TAG to characterise the 'metabolic load index'. (Q30244149) (← links)
- Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes. (Q30253045) (← links)
- The glucose triad and its role in comprehensive glycaemic control: current status, future management (Q30393989) (← links)
- Current concepts in blood glucose monitoring (Q30437091) (← links)
- Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes (Q30666747) (← links)
- Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis (Q30697552) (← links)
- Epidemiological data on postprandial glycaemia. (Q31106389) (← links)
- Influence of smoking and diet on glycated haemoglobin and 'pre-diabetes' categorisation: a cross-sectional analysis (Q31150222) (← links)
- Who should benefit from the use of alpha-glucosidase inhibitors? (Q33438955) (← links)
- Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial (Q33466598) (← links)
- Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses (Q33488897) (← links)
- Using meal-based self-monitoring blood glucose (SMBG) data to guide dietary recommendations in patients with diabetes (Q33516513) (← links)
- Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy (Q33587812) (← links)
- Evidence-based clinical use of insulin premixtures (Q33591271) (← links)
- Target for glycemic control: concentrating on glucose (Q33610724) (← links)
- Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond (Q33610830) (← links)
- Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines (Q33610842) (← links)
- Self-monitoring of blood glucose as part of the integral care of type 2 diabetes (Q33610848) (← links)
- Structured self-monitoring of blood glucose reduces glycated hemoglobin in insulin-treated diabetes (Q33628249) (← links)
- Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring (Q33633690) (← links)
- Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus (Q33658772) (← links)
- Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters (Q33727475) (← links)
- Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study (Q33732577) (← links)
- The incretin system and cardiometabolic disease (Q33776092) (← links)
- Relationship between modified homeostasis model assessment/correlative serum factors and diabetic retinopathy among type 2 diabetics with insulin therapy in Guangzhou, China (Q33794986) (← links)
- Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach (Q33805824) (← links)
- Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk (Q33813768) (← links)
- The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice (Q33815267) (← links)
- MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. (Q33833542) (← links)
- Identifying and meeting the challenges of insulin therapy in type 2 diabetes (Q33863413) (← links)
- Upper gastrointestinal function and glycemic control in diabetes mellitus (Q33869207) (← links)
- Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years (Q33884913) (← links)
- Associations between features of glucose exposure and A1C: the A1C-Derived Average Glucose (ADAG) study (Q33930187) (← links)
- Caffeine modifies blood glucose availability during prolonged low-intensity exercise in individuals with type-2 diabetes (Q34009752) (← links)